Aislinn Antrim, MA, Assistant Managing Editor

Ketamine Wellness Centers also offers a Hero Discount at clinics to cover partial out-of-pocket costs for military veterans and first responders not covered by the VA-CCN partnerships.

The smartphone group were nearly 4 times more likely to have their wound infection diagnosed within 7 days of their surgery compared to the routine care group.

The study’s identification of a network of possible candidate genes to carefully control for mutations could alter the future clinical implementation of CRISPR.

Pembrolizumab demonstrated a statistically significant improvement in disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

If authorized, ritonavir could be prescribed broadly as an at-home treatment to help reduce COVID-19 severity, hospitalizations, and deaths, as well as to reduce the probability of infection following exposure among adults.

Drug dose and monitoring should be individualized based on patients’ unique bone marrow health profile with their age, comorbidities, and prior marrow toxic drug use accounted for.

The FDA is currently reviewing a New Drug Application for vadadustat in this patient population, and a Prescription Drug User Fee Act date has been set for March 29, 2022.

In addition to the prevention of disease in children, COVID-19 vaccination can also limit disruptions in school attendance so that children can participate safely in school and other activities.

Pfizer and BioNTech have also announced that they will be providing the US government with an additional 50 million of the 10 μg doses, with an expected delivery by April 30, 2022.

Patients undergoing chemotherapy had lower COVID-19 antibody levels than patients undergoing targeted therapy following vaccination.

Public recognition of their role has increased exponentially during the COVID-19 pandemic.

Data show 99.2% of children 5 to 11 years of age achieved a seroresponse by 1 month after completing the 2-dose vaccine series.

The FDA has authorized the expanded use of COVID-19 booster doses in eligible populations, including a single dose of the Moderna vaccine and the Johnson & Johnson vaccine.

Exercise can complement other treatments for prostate cancer, including androgen deprivation therapy, which can lead to significant reduction in lean mass and an increase in fat mass.

As the first nasal spray for dry eye disease, varenicline solution nasal spray could be especially helpful for patients who have difficulty administering eye drops.

The approval marks the first and only cell-based influenza vaccine approved in the United States.

A booster shot of the Johnson & Johnson single-shot vaccine administered 56 days after the initial shot provided 94% protection against COVID-19.

Although the advisory committee’s recommendation is not binding, the FDA will take their recommendation into consideration when making a final decision on authorization of the 50-µg booster dose.

The authorization includes strict marketing restrictions on manufacturers, including restrictions on digital, radio, and television advertising, to reduce the potential for youth exposure.

Adults 40 to 59 years of age should consult their clinician before taking aspirin, and adults 60 years of age and older should stop aspirin use for the prevention of cardiovascular disease.

The authors said stigmatization threatens societal cohesion during times of national upheaval, such as during a pandemic.

Patients receiving sacituzumab govitecan also reported lower symptomatic impact of fatigue, pain, dyspnea, and insomnia.

The existence of immunoglobulin G antibodies specifically indicates recent or prior infection and can help identify individuals with an adaptive immune response to SARS-CoV-2.

Vaccine efficacy was 93% against the Delta variant at 1 month after the 2-dose vaccine regimen, although it fell to 53% after 4 months.

The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson’s single-shot vaccine administered 56 days after the primary dose provided 94% protection against symptomatic COVID-19.

Molnupiravir reduced the risk of hospitalization or death by approximately 50% among patients with COVID-19 who received the drug.

Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.